Text Size

Prostate Cancer Nomograms : Disclaimer

The prediction tools (also known as prognostic nomograms) available on Memorial Sloan Kettering Cancer Center's ("MSK") website use algorithms or mathematical formulas to estimate the probability of a particular outcome. They are for general health information only. The tools have not been reviewed or approved by any regulatory agencies in the United States or elsewhere, and are not intended for use as a medical device. The tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem. Users of the prediction tools should not rely on any resulting information for their own health problems. Outputs from these tools are estimates based on survival models built from databases of large numbers of patients. The predictions suggested by these tools may not apply to a given individual. A licensed clinician should always be consulted for any health problem(s) or medical condition(s).

Users agree to use the prediction tools for educational and/or research purposes only, and not for any commercial purposes, including the distribution, licensing, or sale of their content to any other person or entity, whether alone or in combination with other materials, or the incorporation of any of the prediction tools into any commercial product.

MSK makes no warranties, nor express or implied representations whatsoever, regarding the accuracy, completeness, timeliness, comparative or controversial nature, or usefulness of any information contained or referenced in the prediction tools. MSK does not assume any risk whatsoever for use of the prediction tools or the information contained therein. As health-related information changes frequently, information contained in the prediction tools may be outdated, incomplete, or incorrect.

Use of the prediction tools does not create an express or implied physician-patient relationship. MSK does not endorse or claim validity for the prediction tools found on MSK's website. The activities and products of MSK and its developers and agents (collectively MSK) are not endorsed by past, present, or future employers. MSK does not record specific prediction tool user information and does not contact users of the prediction tools.

Users are advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue that users might have at any time, now or in the future. In using the prediction tools, users agree that neither MSK nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to the use of any information resulting from the prediction tools on MSK's website.

I accept all of the above terms by clicking here or by any further use of this service.
I do not accept all of the above terms.

Prostate Cancer Nomograms: PSA Doubling Time

This tool can be used to calculate the rate of rise of PSA, expressed as the velocity in nanograms/ml/year, or the PSA doubling time, in months or years. The most important values to enter are the date/PSA value for each PSA measured over the last 12 months. Alternately, if at least three PSA values are available, enter all PSA values after receiving radical prostatectomy, beginning with the lowest PSA value. (Note: Disregard any PSA values obtained after hormonal therapy was begun.) To learn more, visit our Frequently Asked Questions.

CalculateClearEnter Your Information


(Month / Date / Year)
ng/ml
(> 0.1)

Your Results

Months
Slope Log (PSA)
Doubling Time
Velocity
Years
Slope Log (PSA)
Doubling Time
Velocity
Make an Appointment Call us to schedule an appointment or contact us online Contact Us

Learn More About Your Results

PSA Doubling Time

PSA Doubling Time can be an indicator of biochemical and clinical progression. This tool predicts the changes in PSA levels over time.

Supporting Publication

Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999 May 5;281(17):1591-7.